Blau Farmacêutica (B3: BLAU3) stock: the official figures
Blau Farmacêutica (Blau Farmacêutica S.A.) is listed on B3, the São Paulo stock exchange, under the ticker BLAU3. In fiscal 2025 it reported revenue of BRL 1,702m and a net profit of BRL 295.0m, according to the annual accounts it filed with the regulator.
Identifiers for Blau Farmacêutica: CNPJ 58.430.828/0001-60.
Fiscal 2025 figures
| Item | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | BRL 1,702m | BRL 1,754m | −3.0% |
| Operating profit | BRL 354.4m | BRL 328.8m | +7.8% |
| Net profit | BRL 295.0m | BRL 217.2m | +35.8% |
| Operating margin | 20.8% | 18.7% | +2.1 pts |
| Net margin | 17.3% | 12.4% | +4.9 pts |
| Total assets | BRL 3,635m | BRL 3,412m | +6.5% |
| Equity | BRL 2,272m | BRL 2,164m | +5.0% |
| Cash | BRL 45.6m | BRL 33.3m | +36.9% |
| Operating cash flow | BRL 290.8m | BRL 507.2m | −42.7% |
Margins are calculated from the filed figures: operating profit and net profit over revenue.
9 fiscal years
| Fiscal year | Revenue | Operating profit | Net profit | Document |
|---|---|---|---|---|
| 2025 | BRL 1,702m | BRL 354.4m | BRL 295.0m | Annual report |
| 2024 | BRL 1,754m | BRL 328.8m | BRL 217.2m | Annual report |
| 2023 | BRL 1,373m | BRL 329.4m | BRL 249.8m | Annual report |
| 2022 | BRL 1,407m | BRL 452.2m | BRL 363.4m | Annual report |
| 2021 | BRL 1,366m | BRL 456.6m | BRL 325.2m | Annual report |
| 2020 | BRL 1,182m | BRL 389.1m | BRL 254.3m | Annual report |
| 2019 | BRL 977.5m | BRL 301.5m | BRL 200.2m | Annual report |
| 2018 | BRL 782.2m | BRL 203.0m | BRL 123.3m | Annual report |
| 2017 | BRL 617.7m | BRL 164.3m | BRL 103.1m | Annual report |
The full income statement, balance sheet and cash flow statement are in the annual accounts of Blau Farmacêutica. Year by year: revenue, net income and dividends paid.
Dividends
In fiscal 2025, Blau Farmacêutica paid BRL 82.0m in dividends, 27.8% of its net profit, according to its cash flow statement.
| Fiscal year | Dividends paid | Share of net profit |
|---|---|---|
| 2025 | BRL 82.0m | 27.8% |
| 2024 | BRL 56.1m | 25.8% |
| 2023 | BRL 66.2m | 26.5% |
| 2022 | BRL 135.5m | 37.3% |
| 2021 | BRL 104.1m | 32.0% |
| 2020 | BRL 326.9m | 128.5% |
| 2019 | BRL 117.8m | 58.8% |
| 2018 | BRL 33.4m | 27.1% |
| 2017 | BRL 43.4m | 42.1% |
Cash paid out as dividends during the fiscal year, including dividends to minority shareholders of subsidiaries when the company does not report them separately. It is not the dividend per share.
Frequently asked questions about Blau Farmacêutica
- How much did Blau Farmacêutica earn in fiscal 2025?
- Blau Farmacêutica reported a net profit of BRL 295.0m for fiscal 2025, on revenue of BRL 1,702m. The year before it reported a net profit of BRL 217.2m.
- Does Blau Farmacêutica pay a dividend?
- In fiscal 2025, Blau Farmacêutica paid BRL 82.0m in dividends, 27.8% of its net profit, according to its cash flow statement.
- Where is Blau Farmacêutica listed?
- Blau Farmacêutica is listed on B3, the São Paulo stock exchange, under the ticker BLAU3.
- Where do the figures for Blau Farmacêutica come from?
- From the annual financial statements (DFP) that Blau Farmacêutica files with the CVM, the Brazilian securities regulator. Each fiscal year links to its filing.
Where each figure comes from
The annual accounts come from the annual financial statements (DFP) that Blau Farmacêutica files with the CVM, the Brazilian securities regulator. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.
More companies from Brazil and the rest of the region: Latin American stocks.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.